BMO Capital raised the firm’s price target on AbbVie to $195 from $187 and keeps an Outperform rating on the shares. The analyst is citing the management’s commentary that the tail of Humira may not be felt until 2026, which is adding to confidence that Humira revenues “will be more durable”. AbbVie shares may open up to more generalists who could start to view the name as a growth option, the firm added.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ABBV: